Investor
News & Events
Financial Reports
Stock Information
Corporate Governance
Contacts & Alerts
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Consortium aims to speed the development and delivery of customized or 'bespoke' gene therapies WASHINGTON, May 12, 2022 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that it has...
Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.25 per share of its common stock, payable on July 29, 2022 to...
Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the Bank of America Securities Health Care Conference in Las Vegas,...
Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the first quarter 2022. For the quarter ended April 1, 2022, net earnings were $1.7 billion, or $2.31 per diluted common...
Danaher Corporation (NYSE: DHR) announced today that its 4.75% Series A Mandatory Convertible Preferred Stock (the "Preferred Stock"), will automatically convert into shares of the Company's...